Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing


Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibcotm CTStm OpTmizertm One Serum-Free Medium (CTS OpTmizer One SFM)*, a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion. As a result, cell therapy manufacturers can use CTS OpTmizer One SFM to help optimize their workflows and get T cell therapies to patients faster.

CTS OpTmizer One SFM's ready-to-use, one-part medium can help cell therapy manufacturers scale their manufacturing from process development to clinical trials and commercial manufacturing while maintaining consistent performance. As part of the cell expansion process, CTS OpTmizer One SFM delivers high cell viability, improved growth and maintains early memory T cell phenotype. In addition, the AOF formulation can help in mitigating risk by reducing opportunities for contamination or inconsistency due to animal-origin (AO) components.

The ability to more-rapidly expand less-differentiated T cells to reach a desired dose can help manufacturers shorten the time to treatment, lower manufacturing costs, increase patient access, and enhance therapeutic efficacy.

OpTmizer One SFM's ready-to-use, one-part medium advances T cell expansion and cell growth while helping cell therapy manufacturers improve overall drug function for both autologous and allogeneic therapies, when compared to other leading AOF T cell media.

"CAR T-cell therapies have emerged as a highly impactful treatment option for blood cancers, helping cure patients who have not responded to traditional therapies," said Tiffani Manolis, vice president and general manager of Thermo Fisher's Cell Culture and Cell Therapy business. "CTS OpTmizer One SFM and our entire Cell Therapy Systems portfolio of products were designed to help cell therapy manufacturers overcome speed, safety and cost challenges to help realize the true potential of these therapies and give new hope to patients around the world."

Workflows featuring CTS OpTmizer One SFM display a high level of consistency across small and large scales and various culture vessels, such as G?Rextm plates, rocking motion bioreactors and stirred tank bioreactors. This flexibility allows CTS OpTmizer One SFM to be leveraged in both autologous and allogeneic workflows. Available as a catalog product in 1 L bottles and 1 L, 5 L, and 10 L bioprocess containers, CTS OpTmizer One SFM is compatible with closed automated instruments such as the Gibcotm CTStm DynaCellecttm Magnetic Separation System and the Gibcotm CTStm Rotea Counterflow Centrifugation System.

The CTS OpTmizer One SFM expands Thermo Fisher Scientific's Gibco Cell Therapy Systems (CTS) portfolio of products. Individually and as a platform, the Gibco CTS portfolio deliver flexibility, efficiency, productivity and scalability across the cell therapy manufacturing workflow. The Gibco CTS portfolio of cell and gene therapy products are GMP manufactured, safety tested and backed by regulatory documentation to help customers transition from discovery through clinical and commercial manufacturing.

To learn more about Gibcotm CTStm OpTmizer One, please visit Thermo Fisher's media for cell therapy page.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

* For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals


These press releases may also interest you

at 00:00
The Riverside Company, a global private investor focused on the smaller end of the middle market, has closed the acquisition of Arbeidsmiljø og Energiteknikk AS (AET), a Norwegian distributor of third-party consumables and laboratory / cleaning...

at 00:00
COEUS Solutions, a leading provider of innovative technologies and services in the life sciences industry, today announces its rebranding to BridgeView Life Sciences ("BridgeView") following a recent spinoff from its former parent company. This marks...

29 avr 2024
General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive...

29 avr 2024
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders.The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction...

29 avr 2024
On April 25, 2024, Waterdrop Inc. ("Waterdrop", the "Company" or "we") , a leading technology platform dedicated to insurance and healthcare service with a positive social impact, released its annual report on Form 20-F for the fiscal year ending...

29 avr 2024
Yesterday, The Kids Mental Health Foundation (KMHF),...



News published on and distributed by: